Sareum Regulatory News (SAR)

15 Nov 2007 12:59

Sareum Holdings PLC15 November 2007 For immediate release 15 November 2007 SAREUM HOLDINGS PLC ("Sareum" or "the Company") AGM Statement At the Company's annual general meeting held today, the following resolutionswere passed unanimously by shareholders on a show of hands. The proxy votes received prior to the meeting on each resolution were asfollows: ORDINARY RESOLUTIONS Votes Discretion Votes Votes For Against Withheld 1.To receive and adopt theDirectors' reportand financial statements for the year 8,724,070 221,058 0 0ended 30 June 2007. 97.53% 2.47% 0% 0% 2. To receive and adopt theRemunerationCommittee report for the year ended 8,679,070 266,058 0 030 June 2007. 7.03% 2.97% 0% 0% 3.To re-elect Dr Paul Harper 8,724,070 221,058 0 0as Director. 97.53% 2.47% 0% 0% 4.To re-elect Mr GiorgioReggiani as 8,576,070 366,058 3,000 0Director. 95.88% 4.09% 0.03% 0% 5.To re-appoint Shipleys LLPas auditors andauthorise the Directors to fix their 8,721,070 221,058 3,000 0remuneration. 97.50% 2.47% 0.03% 0% 6.To authorise Directors for thepurposes ofsection 80 of the Companies Act 1985(theAct) to allot relevant securities (within 8,531,070 366,058 48,000 0the meaning of that section) up to an 95.37% 4.09% 0.54% 0%aggregate nominal amount of £90,000. SPECIAL RESOLUTIONS Votes Discretion Votes Votes For Against Withheld7.Subject to the passing of resolution6, toauthorise Directors, in accordancewithsection 95 of the Act, to allotequity securities (as defined in section 94 ofthe Act) wholly for cash up to an 8,531,070 321,058 93,000 0aggregate nominal amount of £50,000. 95.37% 3.59% 1.04% 0% 8.To authorise the Company to send orsupplydocuments or information toshareholders by making them available on the 8,549,070 266,058 130,000 0Company's 95.58% 2.97% 1.45% 0%website or other electronic means. For further information please contact: Sareum Holdings +44 (0) 1223 497700 Tim Mitchell, Chief Executive Officer Buchanan Communications +44 (0) 20 7466 5000 Tim Anderson, Mary-Jane Johnson Notes for editors: About Sareum Holdings plc Sareum Holdings plc is a structure-based drug discovery business headquarteredin Cambridge, UK. Sareum Limited was formed in August 2003 to discover new drugsfor the treatment of cancer and to provide a range of drug discovery services tothe pharmaceutical industry. Sareum's unique approach aims to halve the time ittakes to discover new drug candidates. A structure-based approach to drug discovery relies on knowledge of thethree-dimensional structure of the proteins that cause disease. Once thestructure is known, potential drugs are designed to 'lock-in' to the proteinwith the aim of reversing or arresting a disease's progression. Knowledge of thestructure of the potential drugs and how they 'lock-in' to the protein permitsthe best potential drug to be discovered. Determining structure is a complextask and requires leading-edge equipment and experienced staff. Sareum'sapproach to structure determination is to produce multiple recombinant proteinsprimarily through a baculovirus expression system and to determine theirstructure using x-ray crystallography. When the structure is determined, the Company's innovative Template Screeningplatform is used to identify novel chemical starting material designed tointeract with the target protein. Sareum then uses its high-throughput medicinalchemistry platform to rapidly optimise these molecules and develop the mostpromising into potential drug candidates. Sareum provides its specialist drug discovery capabilities to partners in thepharmaceutical and biotechnology industries. The Company aims to successfullydeliver: Programmes for complete gene-to-candidate structure-based discovery;projects to accelerate or improve the productivity of specific activities; anddrug candidates for licensing at the Phase I or Phase II clinical trials stage. Sareum joined the AIM market of the London Stock Exchange in October 2004 andtrades under the symbol SAR. For further information, please visitwww.sareum.co.uk This information is provided by RNS The company news service from the London Stock Exchange